Integrated Brain Metabolomics and Network Pharmacology Analysis to Reveal the Improvement Effect of Bai Chan Ting on Parkinson's Disease

被引:3
|
作者
Zhang, Na [1 ]
Fu, Jiaqi [2 ]
Gao, Xin [2 ]
Lu, Fang [2 ]
Lu, Yi [2 ]
Liu, Shumin [2 ]
机构
[1] Heilongjiang Drug Safety Evaluat Ctr, Harbin, Heilongjiang, Peoples R China
[2] Heilongjiang Univ Chinese Med, Inst Tradit Chinese Med, Harbin, Heilongjiang, Peoples R China
基金
中国国家自然科学基金;
关键词
ALDEHYDE DEHYDROGENASE 2; NITRIC-OXIDE; PAEONIFLORIN; INHIBITION; TARGET; INJURY;
D O I
10.1155/2022/6113093
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Background. Baichanting (BCT),a traditional Chinese medicine prescription, is a combination of Acanthopanax senticosus, Paeonia lactiflora, and Uncaria three herbs, which has the effect of benefiting the kidney and calming the liver. The study was aimed at investigating the protective effect of BCT against Parkinson's disease using an integrated strategy of network pharmacology and brain metabolomics. Materials and Methods. By integrating network pharmacology with metabolomic research, the protective effect of BCT against PD was investigated using a transgenic mouse model for alpha-synuclein. The metabolite level and gene level components of BCT that might be anti-PD were separated out. Indicators of behavior and pharmacodynamics were employed to gauge the effectiveness of BCT on PD in the preliminary stages. Network pharmacology, which may be the target of BCT, screened the active substances and target genes. The use of metabolomics to identify potential biomarkers of PD, and then through network pharmacology and metabolic pathways to determine their regulatory enzymes and regulatory genes, improve the pathway mechanism of the disease, has important guiding significance for the in-depth study of the pathogenesis of PD. Results. 101 putative target genes were identified by the network pharmacology analysis in relation to the treatment of PD with BCT. According to the functional enrichment analysis, the proposed mechanism was primarily related to the transport of neurotransmitters, the metabolism of arachidonic acid, dopamine, and alpha-amino acids, as well as the transport of dopamine and the negative regulation of amino acid transport. 25 distinct endogenous metabolites were shown to be potential biomarkers for the BCT for treating PD based on metabolomics. These metabolites were mostly implicated in the important methionine and cysteine, tyrosine, histidine, and arginine and proline metabolic pathways. These results somewhat agreed with those of the network pharmacology analysis. Conclusions. In conclusion, this study showed that BCT could delay the occurrence and development of PD by improving the brain metabolic disorder of alpha-Syn mice, which revealed the mechanism of BCT through multitarget and multipathway treatment, and provided a new explanation for the mechanism of anti-PD action. Our research, on the other hand, demonstrated that the network pharmacology-integrated metabolomics approach was a potent tool for discovering the active ingredients and mechanisms underlying the pharmacological effects of traditional Chinese medicine.
引用
收藏
页数:26
相关论文
共 50 条
  • [31] Abnormal Functional Brain Network in Parkinson's Disease and the Effect of Acute Deep Brain Stimulation
    Li, Zhibao
    Liu, Chong
    Wang, Qiao
    Liang, Kun
    Han, Chunlei
    Qiao, Hui
    Zhang, Jianguo
    Meng, Fangang
    FRONTIERS IN NEUROLOGY, 2021, 12
  • [32] Improvement of Deep Brain Stimulation in Dyskinesia in Parkinson's Disease: A Meta-Analysis
    Liu, Yun
    Li, Feng
    Luo, Hansheng
    He, Qiuguang
    Chen, Lifen
    Cheng, Yuan
    Zhang, Wenbin
    Xie, Zongyi
    FRONTIERS IN NEUROLOGY, 2019, 10
  • [33] Motor function improvement and acceptability of non-invasive brain stimulation in patients with Parkinson's disease: a Bayesian network analysis
    Qiu, Youjia
    Yin, Ziqian
    Wang, Menghan
    Duan, Aojie
    Xie, Minjia
    Wu, Jiang
    Wang, Zhong
    Chen, Gang
    FRONTIERS IN NEUROSCIENCE, 2023, 17
  • [34] Integrated network pharmacology, transcriptomics, and metabolomics analysis to reveal the mechanism of salt Eucommiae cortex in the treatment of chronic kidney disease mineral bone disorders via the PPARG/AMPK signaling pathway
    Shen, Jie
    Liu, Youping
    Wang, Qin
    Chen, Hongping
    Hu, Yuan
    Guo, Xiaohong
    Liu, Xia
    Li, Yanhui
    JOURNAL OF ETHNOPHARMACOLOGY, 2023, 314
  • [35] Systematic analysis of the molecular mechanisms mediated by coffee in Parkinson's disease based on network pharmacology approach
    Li, Fangjun
    Hatano, Taku
    Hattori, Nobutaka
    JOURNAL OF FUNCTIONAL FOODS, 2021, 87
  • [36] Integrating Network Pharmacology, Transcriptomics to Reveal Neuroprotective of Curcumin Activate PI3K / AKT Pathway in Parkinson's Disease
    Cai, Benchi
    Wang, Qitong
    Zhong, Lifan
    Liu, Fang
    Wang, Xinyu
    Chen, Tao
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2024, 18 : 2869 - 2881
  • [37] Integrated analysis and network pharmacology approaches to explore key genes of Xingnaojing for treatment of Alzheimer's disease
    Wang, Meixia
    Wang, Shouyong
    Li, Yong
    Cai, Gaomei
    Cao, Min
    Li, Lanfang
    BRAIN AND BEHAVIOR, 2020, 10 (06):
  • [38] Integrated network analysis identifying potential novel drug candidates and targets for Parkinson's disease
    Pusheng Quan
    Kai Wang
    Shi Yan
    Shirong Wen
    Chengqun Wei
    Xinyu Zhang
    Jingwei Cao
    Lifen Yao
    Scientific Reports, 11
  • [39] Integrated network analysis identifying potential novel drug candidates and targets for Parkinson's disease
    Quan, Pusheng
    Wang, Kai
    Yan, Shi
    Wen, Shirong
    Wei, Chengqun
    Zhang, Xinyu
    Cao, Jingwei
    Yao, Lifen
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [40] Protective Effect of Modified Suanmei-Tang on Metabolic-Associated Fatty Liver Disease: An Integrated Strategy of Network Pharmacology, Metabolomics, and Transcriptomics
    Wang, Chao
    Zhao, Mei
    Yue, Yuanyuan
    Hu, Chao
    Zhou, Chunqiu
    Zhang, Zhongyi
    He, Yunliang
    Luo, Yaqi
    Shen, Tao
    Dang, Sijie
    Yang, Yang
    Zhang, Yong
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2024, 18 : 5161 - 5182